Fibrodysplasia ossificans progressiva: Mechanisms and models of skeletal metamorphosis

DMM Disease Models and Mechanisms

Volumn 5, Issue 6, 2012, Pages 756-762

  Kaplan, Frederick S ^a,b   Chakkalakal, Salin A ^a   Shore, Eileen M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; GLUCOCORTICOID;

BONE DEVELOPMENT; CELLS; CHICK EMBRYO; CHICKEN; CHONDROGENESIS; CLINICAL FEATURE; DROSOPHILA MELANOGASTER; FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; GENE MUTATION; GENETIC DISORDER; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; LYMPHOCYTE; MACROPHAGE; MAST CELL; METAMORPHOSIS; NONHUMAN; NOTE; OSSIFYING MYOSITIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEM CELL; TRANSGENIC MOUSE; ZEBRA FISH;

ACTIVIN RECEPTORS; ANIMALS; BONE DEVELOPMENT; DISEASE MODELS, ANIMAL; HUMANS; METAMORPHOSIS, BIOLOGICAL; MUTATION; MYOSITIS OSSIFICANS;

ANIMALIA; DANIO RERIO; GALLUS GALLUS; MUS;

EID: 84870041193     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.010280     Document Type: Note

References (104)

1. Ahn, J., Serrano de la Peña, L., Shore, E. M. and Kaplan, F. S. (2003). Paresis of a bone morphogenetic protein-antagonist response in a genetic disorder of heterotopic skeletogenesis. J. Bone Joint Surg. Am. 85, 667-674. (Pubitemid 36538716)
2. Bangi, E. and Wharton, K. (2006). Dual function of the Drosophila Alk1/Alk2 ortholog Saxophone shapes the Bmp activity gradient in the wing imaginal disc. Development 133, 3295-3303. (Pubitemid 44501832)
3. Billings, P. C., Fiori, J. L., Bentwood, J. L., O'Connell, M. P., Jiao, X., Nussbaum, B., Caron, R. J., Shore, E. M. and Kaplan, F. S. (2008). Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J. Bone Miner. Res. 23, 305-313. (Pubitemid 351304661)
4. Bocciardi, R., Bordo, D., Di Duca, M., Di Rocco, M. and Ravazzolo, R. (2009). Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur. J. Hum. Genet. 17, 311-318.
5. Carvalho, D. R., Navarro, M. M. M., Martins, B. J., Coelho, K. E., Mello, W. D., Takata, R. I. and Speck-Martins, C. E. (2010). Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients. Clin. Genet. 77, 171-176.
6. Chakkalakal, S. A., Zhang, D., Culbert, A. L., Convente, M. R., Caron, R. J., Wright, A. C., Maidment, A. D. A., Kaplan, F. S. and Shore, E. M. (2012). An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J. Bone Miner. Res. 27, 1746-1756.
7. Cohen, R. B., Hahn, G. V., Tabas, J. A., Peeper, J., Levitz, C. L., Sando, A., Sando, N., Zasloff, M. and Kaplan, F. S. (1993). The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J. Bone Joint Surg. Am. 75, 215-219. (Pubitemid 23093971)
8. Connor, J. M. and Evans, D. A. (1982). Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J. Bone Joint Surg. Br. 64, 76-83. (Pubitemid 12005874)
9. Deirmengian, G. K., Hebela, N. M., O'Connell, M., Glaser, D. L., Shore, E. M. and Kaplan, F. S. (2008). Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J. Bone Joint Surg. Am. 90, 366-374. (Pubitemid 351341049)
10. Derynck, R. and Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584. (Pubitemid 37280136)
11. Einhorn, T. A. and Kaplan, F. S. (1994). Traumatic fractures of heterotopic bone in patients who have fibrodysplasia ossificans progressiva. A report of 2 cases. Clin. Orthop. Relat. Res. 308, 173-177. (Pubitemid 24349324)
12. Fiori, J. L., Billings, P. C., de la Peña, L. S., Kaplan, F. S. and Shore, E. M. (2006). Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J. Bone Miner. Res. 21, 902-909. (Pubitemid 43787997)
13. Forsberg, J. A., Pepek, J. M., Wagner, S., Wilson, K., Flint, J., Andersen, R. C., Tadaki, D., Gage, F. A., Stojadinovic, A. and Elster, E. A. (2009). Heterotopic ossification in high-energy wartime extremity injuries: prevalence and risk factors. J. Bone Joint Surg. Am. 91, 1084-1091.
14. Fukuda, T., Scott, G., Komatsu, Y., Araya, R., Kawano, M., Ray, M. K., Yamada, M. and Mishina, Y. (2006). Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis 44, 159-167. (Pubitemid 43727738)
15. Fukuda, T., Kanomata, K., Nojima, J., Kokabu, S., Akita, M., Ikebuchi, K., Jimi, E., Komori, T., Maruki, Y., Matsuoka, M. et al. (2008). A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem. Biophys. Res. Commun. 377, 905-909.
16. Fukuda, T., Kohda, M., Kanomata, K., Nojima, J., Nakamura, A., Kamizono, J., Noguchi, Y., Iwakiri, K., Kondo, T., Kurose, J. et al. (2009). Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J. Biol. Chem. 284, 7149-7156.
17. Furuya, H., Ikezoe, K., Wang, L. X., Ohyagi, Y., Motomura, K., Fujii, N., Kira, J. and Fukumaki, Y. (2008). A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am. J. Med. Genet. 146A, 459-463. (Pubitemid 351206817)
18. Gannon, F. H., Kaplan, F. S., Olmsted, E., Finkel, G. C., Zasloff, M. A. and Shore, E. (1997). Bone morphogenetic protein 2/4 in early fibromatous lesions of fibrodysplasia ossificans progressiva. Hum. Pathol. 28, 339-343. (Pubitemid 27106087)
19. Gannon, F. H., Valentine, B. A., Shore, E. M., Zasloff, M. A. and Kaplan, F. S. (1998). Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 346, 19-25. (Pubitemid 28046863)
20. Gannon, F. H., Glaser, D., Caron, R., Thompson, L. D., Shore, E. M. and Kaplan, F. S. (2001). Mast cell involvement in fibrodysplasia ossificans progressiva. Hum. Pathol. 32, 842-848. (Pubitemid 32803986)
21. Gazzerro, E. and Canalis, E. (2006). Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord. 7, 51-65. (Pubitemid 46044349)
22. Glaser, D. L., Rocke, D. M. and Kaplan, F. S. (1998). Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 346, 110-116. (Pubitemid 28046874)
23. Glaser, D. L., Economides, A. N., Wang, L., Liu, X., Kimble, R. D., Fandl, J. P., Wilson, J. M., Stahl, N., Kaplan, F. S. and Shore, E. M. (2003). In vivo somatic cell gene transfer of an engineered Noggin mutein prevents BMP4-induced heterotopic ossification. J. Bone Joint Surg. Am. 85, 2332-2342. (Pubitemid 37499642)
24. Gregson, C. L., Hollingworth, P., Williams, M., Petrie, K. A., Bullock, A. N., Brown, M. A., Tobias, J. H. and Triffitt, J. T. (2011). A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone 48, 654-658.
25. Groppe, J. C., Shore, E. M. and Kaplan, F. S. (2007). Functional modeling of the ACVR1 (R206H) mutation in FOP. Clin. Orthop. Relat. Res. 462, 87-92. (Pubitemid 47367848)
26. Groppe, J. C., Wu, J., Shore, E. M. and Kaplan, F. S. (2011). In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 194, 291-295.
27. Gugala, Z., Olmsted-Davis, E. A., Gannon, F. H., Lindsey, R. W. and Davis, A. R. (2003). Osteoinduction by ex vivo adenovirus-mediated BMP2 delivery is independent of cell type. Gene Ther. 10, 1289-1296. (Pubitemid 36987119)
28. Hebela, N., Shore, E. M. and Kaplan, F. S. (2005). Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva: the role of environment in the progression of heterotopic ossification. CRBMM 3, 205-208. (Pubitemid 41400336)
29. Hegyi, L., Gannon, F. H., Glaser, D. L., Shore, E. M., Kaplan, F. S. and Shanahan, C. M. (2003). Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification? J. Pathol. 201, 141-148. (Pubitemid 37121213)
30. Hong, C. C. and Yu, P. B. (2009). Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev. 20, 409-418.
31. Huse, M., Chen, Y. G., Massagué, J. and Kuriyan, J. (1999). Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 96, 425-436. (Pubitemid 29077596)
32. Huse, M., Muir, T. W., Xu, L., Chen, Y. G., Kuriyan, J. and Massagué, J. (2001). The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol. Cell 8, 671-682. (Pubitemid 32946943)
33. Janoff, H. B., Muenke, M., Johnson, L. O., Rosenberg, A., Shore, E. M., Okereke, E., Zasloff, M. and Kaplan, F. S. (1996). Fibrodysplasia ossificans progressiva in two half-sisters: evidence for maternal mosaicism. Am. J. Med. Genet. 61, 320-324.
34. Kan, L., Hu, M., Gomes, W. A. and Kessler, J. A. (2004). Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am. J. Pathol. 165, 1107-1115. (Pubitemid 39297718)
35. Kan, L., Liu, Y., McGuire, T. L., Berger, D. M., Awatramani, R. B., Dymecki, S. M. and Kessler, J. A. (2009). Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells 27, 150-156.
36. Kan, L., Lounev, V. Y., Pignolo, R. J., Duan, L., Liu, Y., Stock, S. R., McGuire, T. L., Lu, B., Gerard, N. P., Shore, E. M. et al. (2011). Substance P signaling mediates BMP-dependent heterotopic ossification. J. Cell. Biochem. 112, 2759-2772.
37. Kaplan, F. S. and Glaser, D. L. (2005). Thoracic insufficiency syndrome in patients with fibrodysplasia ossificans progressiva. CRBMM 3, 213-216. (Pubitemid 41400338)
38. Kaplan, F. S. and Shore, E. M. (2011). Derailing heterotopic ossification and RARing to go. Nat. Med. 17, 420-421.
39. Kaplan, F. S., Tabas, J. A. and Zasloff, M. A. (1990). Fibrodysplasia ossificans progressiva: a clue from the fly? Calcif. Tissue Int. 47, 117-125. (Pubitemid 20238176)
40. Kaplan, F. S., Tabas, J. A., Gannon, F. H., Finkel, G., Hahn, G. V. and Zasloff, M. A. (1993a). The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. J. Bone Joint Surg. Am. 75, 220-230. (Pubitemid 23093972)
41. Kaplan, F. S., McCluskey, W., Hahn, G., Tabas, J. A., Muenke, M. and Zasloff, M. A. (1993b). Genetic transmission of fibrodysplasia ossificans progressiva. Report of a family. J. Bone Joint Surg. Am. 75, 1214-1220. (Pubitemid 23267913)
42. Kaplan, F. S., Strear, C. M. and Zasloff, M. A. (1994). Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 304, 238-247. (Pubitemid 24230691)
43. Kaplan, F., Sawyer, J., Connors, S., Keough, K., Shore, E., Gannon, F., Glaser, D., Rocke, D., Zasloff, M. and Folkman, J. (1998). Urinary basic fibroblast growth factor. A biochemical marker for preosseous fibroproliferative lesions in patients with fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 346, 59-65. (Pubitemid 28046868)
44. Kaplan, F. S., Glaser, D. L., Hebela, N. and Shore, E. M. (2004). Heterotopic ossification. J. Am. Acad. Orthop. Surg. 12, 116-125.
45. Kaplan, F. S., Shore, E. M., Gupta, R., Billings, P. C., Glaser, D. L., Pignolo, R. J., Graf, D. and Kamoun, M. (2005a). Immunological features of fibrodysplasia ossificans progressiva and the dysregulated BMP4 pathway. CRBMM 3, 189-194.
46. Kaplan, F. S., Glaser, D. L., Shore, E. M., Deirmengian, G. K., Gupta, R., Delai, P., Morhart, R., Smith, R., Le Merrer, M., Rogers, J. G. et al. (2005b). The phenotype of fibrodysplasia ossificans progressiva. CRBMM 3, 183-188. (Pubitemid 41400332)
47. Kaplan, F. S., Glaser, D. L., Shore, E. M., Pignolo, R. J., Xu, M., Zhang, Y., Senitzer, D., Forman, S. J. and Emerson, S. G. (2007a). Hematopoietic stem-cell contribution to ectopic skeletogenesis. J. Bone Joint Surg. Am. 89, 347-357. (Pubitemid 46214354)
48. Kaplan, F. S., Glaser, D. L., Pignolo, R. J. and Shore, E. M. (2007b). A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opin. Biol. Ther. 7, 705-712. (Pubitemid 46710933)
49. Kaplan, F. S., Le Merrer, M., Glaser, D. L., Pignolo, R. J., Goldsby, R. E., Kitterman, J. A., Groppe, J. and Shore, E. M. (2008a). Fibrodysplasia ossificans progressiva. Best Pract. Res. Clin. Rheumatol. 22, 191-205. (Pubitemid 351325734)
50. Kaplan, F. S., Xu, M., Glaser, D. L., Collins, F., Connor, M., Kitterman, J., Sillence, D., Zackai, E., Ravitsky, V., Zasloff, M. et al. (2008b). Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 121, e1295-e1300.
51. Kaplan, F. S., Xu, M., Seemann, P., Connor, J. M., Glaser, D. L., Carroll, L., Delai, P., Fastnacht-Urban, E., Forman, S. J., Gillessen-Kaesbach, G. et al. (2009a). Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat. 30, 379-390.
52. Kaplan, F. S., Pignolo, R. J. and Shore, E. M. (2009b). The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev. 20, 399-407.
53. Kaplan, F. S., Zasloff, M. A., Kitterman, J. A., Shore, E. M., Hong, C. C. and Rocke, D. M. (2010a). Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J. Bone Joint Surg. Am. 92, 686-691.
54. Kaplan, F. S., Groppe, J. C., Seemann, P., Pignolo, R. J. and Shore, E. M. (2010b). Fibrodysplasia ossificans progressiva: developmental implications of a novel metamorphogene. In Bone and Development (ed. F. Bronner, M. C. Farach-Carson and H. I. Roach). London, UK: Springer-Verlag.
55. Kaplan, F. S., Lounev, V. Y., Wang, H., Pignolo, R. J. and Shore, E. M. (2011). Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Ann. N. Y. Acad. Sci. 1237, 5-10.
56. Kaplan, J., Kaplan, F. S. and Shore, E. M. (2012). Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther. 19, 786-790.
57. Kitterman, J. A., Kantanie, S., Rocke, D. M. and Kaplan, F. S. (2005). Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 116, e654-e661. (Pubitemid 46056396)
58. Kussmaul, W. G., Esmail, A. N., Sagar, Y., Ross, J., Gregory, S. and Kaplan, F. S. (1998). Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 346, 104-109. (Pubitemid 28046873)
59. Lanchoney, T. F., Cohen, R. B., Rocke, D. M., Zasloff, M. A. and Kaplan, F. S. (1995). Permanent heterotopic ossification at the injection site after diphtheria-tetanuspertussis immunizations in children who have fibrodysplasia ossificans progressiva. J. Pediatr. 126, 762-764.
60. Le, V. Q. and Wharton, K. A. (2012). Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva. Dev. Dyn. 241, 200-214.
61. Levy, C. E., Lash, A. T., Janoff, H. B. and Kaplan, F. S. (1999). Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am. J. Audiol. 8, 29-33.
62. Little, S. C. and Mullins, M. C. (2009). Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat. Cell Biol. 11, 637-643.
63. Lounev, V. Y., Ramachandran, R., Wosczyna, M. N., Yamamoto, M., Maidment, A. D., Shore, E. M., Glaser, D. L., Goldhamer, D. J. and Kaplan, F. S. (2009). Identification of progenitor cells that contribute to heterotopic skeletogenesis. J. Bone Joint Surg. Am. 91, 652-663.
64. Luchetti, W., Cohen, R. B., Hahn, G. V., Rocke, D. M., Helpin, M., Zasloff, M. and Kaplan, F. S. (1996). Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 81, 21-25. (Pubitemid 126812873)
65. Lutwak, L. (1964). Myositis ossificans progressiva: mineral, metabolic, and radioactive calcium studies of the effects of hormones. Am. J. Med. 37, 269-293.
66. Maeder, T. (1998). A few hundred people turned to bone. The Atlantic Monthly 281, 81-89.
67. Mahboubi, S., Glaser, D. L., Shore, E. M. and Kaplan, F. S. (2001). Fibrodysplasia ossificans progressiva. Pediatr. Radiol. 31, 307-314. (Pubitemid 32422034)
68. Medici, D., Shore, E. M., Lounev, V. Y., Kaplan, F. S., Kalluri, R. and Olsen, B. R. (2010). Conversion of vascular endothelial cells into multipotent stem-like cells. Nat. Med. 16, 1400-1406.
69. Mohler, E. R., 3rd, Gannon, F., Reynolds, C., Zimmerman, R., Keane, M. G. and Kaplan, F. S. (2001). Bone formation and inflammation in cardiac valves. Circulation 103, 1522-1528. (Pubitemid 32226259)
70. Moore, R. E., Dormans, J. P., Drummond, D. S., Shore, E. M., Kaplan, F. S. and Auerbach, J. D. (2009). Chin-on-chest deformity in patients with fibrodysplasia ossificans progressiva. A case series. J. Bone Joint Surg. Am. 91, 1497-1502.
71. Neal, B., Gray, H., MacMahon, S. and Dunn, L. (2002). Incidence of heterotopic bone formation after major hip surgery. ANZ J. Surg. 72, 808-821. (Pubitemid 35370622)
72. Petrie, K. A., Lee, W. H., Bullock, A. N., Pointon, J. J., Smith, R., Russell, R. G., Brown, M. A., Wordsworth, B. P. and Triffitt, J. T. (2009). Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. PLoS ONE 4, e5005.
73. Pignolo, R. J. and Foley, K. L. (2005). Nonhereditary heterotopic ossification. CRBMM 3, 261-266.
74. Pignolo, R. J., Suda, R. K. and Kaplan, F. S. (2005). The fibrodysplasia ossificans progressiva lesion. CRBMM 3, 195-200. (Pubitemid 41400334)
75. Potter, B. K., Burns, T. C., Lacap, A. P., Granville, R. R. and Gajewski, D. (2006). Heterotopic ossification in the residual limbs of traumatic and combat-related amputees. J. Am. Acad. Orthop. Surg. 14, S191-S197.
76. Ratbi, I., Borcciadi, R., Regragui, A., Ravazzolo, R. and Sefiani, A. (2010). Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva. Clin. Rheumatol. 29, 119-121.
77. Rocke, D. M., Zasloff, M., Peeper, J., Cohen, R. B. and Kaplan, F. S. (1994). Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 301, 243-248. (Pubitemid 24119281)
78. Rogers, J. G. and Chase, G. A. (1979). Paternal age effect in fibrodysplasia ossificans progressiva. J. Med. Genet. 16, 147-148. (Pubitemid 9164910)
79. Salisbury, E., Rodenberg, E., Sonnet, C., Hipp, J., Gannon, F. H., Vadakkan, T. J., Dickinson, M. E., Olmsted-Davis, E. A. and Davis, A. R. (2011). Sensory nerve induced inflammation contributes to heterotopic ossification. J. Cell. Biochem. 112, 2748-2758.
80. Scarlett, R. F., Rocke, D. M., Kantanie, S., Patel, J. B., Shore, E. M. and Kaplan, F. S. (2004). Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin. Orthop. Relat. Res. 423, 275-279. (Pubitemid 38787751)
81. Schaffer, A. A., Kaplan, F. S., Tracy, M. R., O'Brien, M. L., Dormans, J. P., Shore, E. M., Harland, R. M. and Kusumi, K. (2005). Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome: clues from the BMP signaling pathway. Spine 30, 1379-1385. (Pubitemid 41754860)
82. Schmierer, B. and Hill, C. S. (2007). TGF-beta-SMAD signal transduction: molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 8, 970-982. (Pubitemid 350174642)
83. Serrano de la Peña, L., Billings, P. C., Fiori, J. L., Ahn, J., Kaplan, F. S. and Shore, E. M. (2005). Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J. Bone Miner. Res. 20, 1168-1176. (Pubitemid 40863804)
84. Shafritz, A. B., Shore, E. M., Gannon, F. H., Zasloff, M. A., Taub, R., Muenke, M. and Kaplan, F. S. (1996). Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N. Engl. J. Med. 335, 555-561. (Pubitemid 26272310)
85. Shah, P. B., Zasloff, M. A., Drummond, D. and Kaplan, F. S. (1994). Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J. Bone Joint Surg. Am. 76, 1442-1450. (Pubitemid 24355959)
86. Shen, Q., Little, S. C., Xu, M., Haupt, J., Ast, C., Katagiri, T., Mundlos, S., Seemann, P., Kaplan, F. S., Mullins, M. C. et al. (2009). The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J. Clin. Invest. 119, 3462-3472.
87. Shi, Y. and Massagué, J. (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700. (Pubitemid 36724933)
88. Shimono, K., Tung, W. E., Macolino, C., Chi, A. H.-T., Didizian, J. H., Mundy, C., Chandraratna, R. A., Mishina, Y., Enomoto-Iwamoto, M., Pacifici, M. et al. (2011). Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-g agonists. Nat. Med. 17, 454-460.
89. Shirkhoda, A., Armin, A.-R., Bis, K. G., Makris, J., Irwin, R. B. and Shetty, A. N. (1995). MR imaging of myositis ossificans: variable patterns at different stages. J. Magn. Reson. Imaging 5, 287-292.
90. Shore, E. M. and Kaplan, F. S. (2010). Inherited human diseases of heterotopic bone formation. Nat. Rev. Rheumatol. 6, 518-527.
91. Shore, E. M., Feldman, G. J., Xu, M. and Kaplan, F. S. (2005). The genetics of fibrodysplasia ossificans progressiva. CRBMM 3, 201-204. (Pubitemid 41400335)
92. Shore, E. M., Xu, M., Feldman, G. J., Fenstermacher, D. A., Cho, T.-J., Choi, I. H., Connor, J. M., Delai, P., Glaser, D. L., LeMerrer, M. et al. (2006). A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat. Genet. 38, 525-527.
93. Song, G. A., Kim, H. J., Woo, K. M., Baek, J. H., Kim, G. S., Choi, J. Y. and Ryoo, H. M. (2010). Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J. Biol. Chem. 285, 22542-22553.
94. Twombly, V., Bangi, E., Le, V., Malnic, B., Singer, M. A. and Wharton, K. A. (2009). Functional analysis of saxophone, the Drosophila gene encoding the BMP type I receptor ortholog of human ALK1/ACVRL1 and ACVR1/ALK2. Genetics 183, 563-579.
95. Urist, M. R. (1965). Bone: formation by autoinduction. Science 150, 893-899.
96. van Dinther, M., Visser, N., de Gorter, D. J., Doorn, J., Goumans, M. J., de Boer, J. and ten Dijke, P. (2010). ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J. Bone Miner. Res. 25, 1208-1215.
97. van Kuijk, A. A., Geurts, A. C. H. and van Kuppevelt, H. J. M. (2002). Neurogenic heterotopic ossification in spinal cord injury. Spinal Cord 40, 313-326. (Pubitemid 34756209)
98. Whyte, M. P., Wenkert, D., Demertzis, J. L., DiCarlo, E. F., Westenberg, E. and Mumm, S. (2012). Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1. J. Bone Miner. Res. 27, 729-737.
99. Wosczyna, M. N., Biswas, A. A., Cogswell, C. A. and Goldhamer, D. J. (2012). Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J. Bone Miner. Res. 27, 1004-1017.
100. Wozney, J. M., Rosen, V., Celeste, A. J., Mitsock, L. M., Whitters, M. J., Kriz, R. W., Hewick, R. M. and Wang, E. A. (1988). Novel regulators of bone formation: molecular clones and activities. Science 242, 1528-1534. (Pubitemid 19023695)
101. Wu, M. Y. and Hill, C. S. (2009). Tgf-beta superfamily signaling in embryonic development and homeostasis. Dev. Cell 16, 329-343.
102. Yu, P. B., Deng, D. Y., Lai, C. S., Hong, C. C., Cuny, G. D., Bouxsein, M. L., Hong, D. W., McManus, P. M., Katagiri, T., Sachidanandan, C. et al. (2008). BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat. Med. 14, 1363-1369.
103. Zasloff, M. A., Rocke, D. M., Crofford, L. J., Hahn, G. V. and Kaplan, F. S. (1998). Treatment of patients who have fibrodysplasia ossificans progressiva with isotretinoin. Clin. Orthop. Relat. Res. 346, 121-129. (Pubitemid 28046876)
104. Zhang, D., Schwarz, E. M., Rosier, R. N., Zuscik, M. J., Puzas, J. E. and O'Keefe, R. J. (2003). ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J. Bone Miner. Res. 18, 1593-1604. (Pubitemid 37022917)